Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells

Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells

US Patent 11407806 · Granted Aug 9, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Mutant variants of PD-1 receptor with selective binding to PD-L1 and uses thereo2025
Compounds and methods for treatment of bacterial infections2025
Engineered PD-1 variants2024
Prevention and treatment of viral infections2022
Engineered PD-1 variants2022
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and metho2022
Broad spectrum viral inhibitor2022
Methods for high throughput receptor:ligand identification2022
TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for 2021
Tumor necrosis factor 1B (TNF-1B) mutants and methods of use thereof to screen f2020
TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for 2019
Methods for high throughput receptor:ligand identification2018